🔎 Trials Near Me

Akèy › Neuroblastom › Alabama › Birmingham

Etid klinik pou Neuroblastom nan Birmingham, AL

8 etid pou Neuroblastom ap chèche patisipan nan sit nan ak bò kote Birmingham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Ap rekriteFaz 3
  • Children's Hospital of Alabama, Birmingham
Jiska laj 30 · Tout sèks · Mizajou Oct 2, 2026 · NCT06172296

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Ap rekriteFaz 2
  • University of Alabama/Children's of Alabama, Birmingham
Jiska laj 22 · Tout sèks · Mizajou Sep 4, 2026 · NCT02559778

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Ap rekriteFaz 1/2
  • University of Alabama/Children's of Alabama, Birmingham
Jiska laj 26 · Tout sèks · Mizajou Sep 3, 2026 · NCT06465199

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Ap rekriteFaz 1/2
  • University of Alabama/Children's of Alabama, Birmingham
Jiska laj 30 · Tout sèks · Mizajou Sep 3, 2026 · NCT06541262

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Ap rekriteFaz 3
  • Children's Hospital of Alabama, Birmingham
365 Days – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Ap rekriteFaz 1/2
  • Children's Hospital of Alabama, Birmingham
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Ap rekriteFaz 2
  • University of Alabama/Children's of Alabama, Birmingham
12 Months – 21 Years · Tout sèks · Mizajou Aug 12, 2026 · NCT05489887

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Ap rekriteFaz 2
  • Children's Hospital of Alabama/UAB, Birmingham
18 Months – 40 Years · Tout sèks · Mizajou Aug 12, 2025 · NCT05135975

Etid Neuroblastom nan lòt vil

Lòt etid nan Birmingham

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.